Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Albert Widmer
Observed names:
A Widmer,
A. F. Widmer,
A. Widmer,
Widmer, A,
Widmer, A.,
Widmer, Albert
show all 6
Institution:
Novartis (Switzerland)
Observed institutions:
Novartis (Switzerland),
Memorial University of Newfoundland,
Novartis (United States),
Centralny Szpital Kliniczny,
Central Clinical Hospital,
Wojskowy Instytut Medyczny,
University of Genoa
show all 7
OpenAlex ID:
A5079356358
Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density
2002
·
Ian R. Reid
, Jacques P. Brown
, et al.
·
New England Journal of Medicine
·
876
PDF
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
2009
·
Helen J. Lachmann
, Isabelle Kone-Paut
, et al.
·
New England Journal of Medicine
·
869
PDF
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
2019
·
A. Deodhar
, P. J. Mease
, et al.
·
Arthritis Research & Therapy
·
292
PDF
Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes
2011
·
Jasmin B Kuemmerle-Deschner
, E Hachulla
, et al.
·
Annals of the Rheumatic Diseases
·
224
Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study
2011
·
Rieke Alten
, Juan Gomez-Reino
, et al.
·
BMC Musculoskeletal Disorders
·
153
PDF
Intravenous Zoledronic Acid in Postmenopausal Women With Low Bone Mineral Density
2003
·
Ian R. Reid
, Jacques P. Brown
, et al.
·
Obstetrical & Gynecological Survey
·
93
Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study
2019
·
Alan J. Kivitz
, Peter Nash
, et al.
·
Rheumatology and Therapy
·
85
PDF
Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study
2016
·
Witold Tlustochowicz
, Proton Rahman
, et al.
·
The Journal of Rheumatology
·
43
PDF
An experimental contribution to the question of the existence of lighting-like discharges in dust clouds
1977
·
P. Boschung
, W. Hilgner
, et al.
·
Journal of Electrostatics
·
34
SAT0579 Secukinumab Safety and Tolerability in Patients with Active Psoriatic Arthritis: Pooled Safety Analysis of Two Phase 3, Randomized, Controlled Trials (Future 1 and Future 2)
2015
·
P. Mease
, I.B. McInnes
, et al.
·
Annals of the Rheumatic Diseases
·
9
Efficacy and Safety of Canakinumab in Patients with Cryopyrin Associated Periodic Syndrome: Results From Meta-Analysis of 5 Studies
2012
·
Lachmann, HJ
, Kuemmerle-Deschner, JB
, et al.
·
UCL Discovery (University College London)
·
5
THU0325 Secukinumab demonstrates a consistent safety profile with up to 5 years treatment in patients with psoriatic arthritis and moderate to severe plaque psoriasis: updated pooled safety analyses
2018
·
P.J. Mease
, I.B. McInnes
, et al.
·
Annals of the Rheumatic Diseases
·
3
PDF
Secukinumab Safety and Tolerability in Patients with Active Psoriatic Arthritis and Psoriasis: Results From a Pooled Safety Analysis
2016
·
Peter Nash
, Philip Mease
, et al.
·
Internal Medicine Journal
·
2
Cytokines and inflammatory mediators: 25. Certolizumab Pegol has a Different Profile from the other Anti-TNFS, Including Golimumab, in a Variety of in Vitro Assays
2011
·
A. Nesbitt
, G. Fossati
, et al.
·
Lara D. Veeken
·
2
257 Secukinumab demonstrates a consistent safety profile with up to 5 years’ treatment in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses
2019
·
Iain B McInnes
, Philip J Mease
, et al.
·
Lara D. Veeken
·
1
Efficacy and Safety of Canakinumab (ACZ885), A Fully Human Anti-interleukin 1 beta Antibody, in Cryopyrin Associated Periodic Fever Syndrome: Results of a Multicenter, Randomized, Double-blind, Phase III Study
2008
·
Lachmann, HJ
, Kone-Paut, I
, et al.
·
UCL Discovery (University College London)
·
1
Experimente zur Frage nach blitzähnlichen Entladungen aufgeladener Staubwolken
1975
·
P. Boschung
, W. Hilgner
, et al.
·
Chemie Ingenieur Technik
·
1
THU0398 Secukinumab sustains individual clinical responses over time in patients with active ankylosing spondylitis: 2-year results from a phase 3 trial, measure 2
2017
·
X Baraliakos
, M Schiff
, et al.
·
Annals of the Rheumatic Diseases
PDF
Canakinumab Provides Rapid Improvement With Sustained Clinical and Inflammatory Remission in Cryopyrin-associated Periodic Syndrome Patients Across All Severity Phenotypes
2011
·
Hawkins, PN
, Kuemmerle-Deschner, JB
, et al.
·
UCL Discovery (University College London)
Efficacy and Safety of Canakinumab in a Large Cohort of Cryopyrin-Associated Periodic Syndrome (CAPS) Patients across All Severity Phenotypes
2011
·
R. Cartwright
, J. Smith
, et al.
·
Journal of Allergy and Clinical Immunology
PDF
Detection of tuberculosis by extensive screening in a patient with rheumatoid arthritis prior to anti-TNF-α therapy
2006
·
A. Iseli
, H. D. Hüllstrung
, et al.
·
Lara D. Veeken
Show more works
View as search
Works count:
25
Citation count:
2,694
H-index:
9
I10-index:
9
Year
Topic
Type
